• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[高血压或冠状动脉粥样硬化性心脏病患者组织因子(TF)和组织因子途径抑制物(TFPI)活性的变化]

[Changes of TF and TFPI activities in patients with hypertension or coronary atherosclerotic heart disease].

作者信息

Xiao Z, Wang W, Han J, He X, Li J

机构信息

Department of Gerontology, Xianya Hospital, Hunan Medical University, Changsha 410008.

出版信息

Hunan Yi Ke Da Xue Xue Bao. 1999;24(3):251-2, 255.

PMID:12016797
Abstract

OBJECT

To investigate the changes of tissue factor (TF) and tissue factor pathway inhibitor(TFPI) activities in patients with hypertension or coronary atherosclerotic heart (CAH) disease.

METHODS

TF activity was measured by two-stage assay, and TFPI activity was detected according to Sandset's method.

RESULTS

Plasma TF activity in both patients with hypertension and patients with CAH disease was higher than that of normal control(P < 0.05).

CONCLUSION

Hypercoagulative state may be involved in the pathogenetic processes of hypertension and CAH diseases. TF and TFPI activities have the likelihood to become the accessory diagnostic indexes for hypertension and CAH diseases.

摘要

目的

探讨高血压或冠状动脉粥样硬化性心脏病(CAH)患者组织因子(TF)和组织因子途径抑制物(TFPI)活性的变化。

方法

采用两步法测定TF活性,按照桑德塞特方法检测TFPI活性。

结果

高血压患者和CAH患者的血浆TF活性均高于正常对照组(P < 0.05)。

结论

高凝状态可能参与高血压和CAH疾病的发病过程。TF和TFPI活性有可能成为高血压和CAH疾病的辅助诊断指标。

相似文献

1
[Changes of TF and TFPI activities in patients with hypertension or coronary atherosclerotic heart disease].[高血压或冠状动脉粥样硬化性心脏病患者组织因子(TF)和组织因子途径抑制物(TFPI)活性的变化]
Hunan Yi Ke Da Xue Xue Bao. 1999;24(3):251-2, 255.
2
[Levels of plasma TF and TFPI activities in patients with acute leukemia].[急性白血病患者血浆组织因子(TF)和组织因子途径抑制物(TFPI)活性水平]
Hunan Yi Ke Da Xue Xue Bao. 2000 Aug 28;25(4):401-2, 405.
3
Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.组织因子与组织因子途径抑制物在冠状动脉粥样硬化中的共定位
J Pathol. 1999 Jun;188(2):180-8. doi: 10.1002/(SICI)1096-9896(199906)188:2<180::AID-PATH338>3.0.CO;2-Q.
4
Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.组织因子、组织途径因子抑制剂与慢性肢体缺血患者动脉粥样硬化的危险因素:初步研究
Int Angiol. 2008 Aug;27(4):296-301.
5
Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.组织因子途径抑制物在冠状动脉疾病中的抗凝与酰胺水解活性比较
Blood Coagul Fibrinolysis. 2000 Apr;11(3):285-91.
6
Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.人类非新月体性肾小球肾炎中的组织因子及其抑制剂——免疫染色与血浆及尿液水平的比较
Nephrol Dial Transplant. 2006 Dec;21(12):3450-7. doi: 10.1093/ndt/gfl365. Epub 2006 Sep 17.
7
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.组织因子和组织因子途径抑制物基因多态性对稳定型冠状动脉疾病中凝血酶生成的影响。
Pathophysiol Haemost Thromb. 2010;37(2-4):98-103. doi: 10.1159/000327491. Epub 2011 May 10.
8
Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.原发性肾小球肾炎患者血浆组织因子及组织因子途径抑制物
Scand J Urol Nephrol. 2007;41(3):237-42. doi: 10.1080/00365590601016511.
9
Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques.组织因子、组织因子途径抑制物与血管内皮生长因子-A在颈动脉粥样硬化斑块中的作用
Eur J Vasc Endovasc Surg. 2005 Jul;30(1):41-7. doi: 10.1016/j.ejvs.2005.02.055.
10
The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.冠心病患者中组织因子途径抑制物(TFPI)、脂蛋白(a)[Lp(a)]及氧化型低密度脂蛋白抗体水平之间的关系。
Clin Biochem. 2005 Jan;38(1):92-6. doi: 10.1016/j.clinbiochem.2004.09.011.